Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.87 |
| ▸ | ADRB1 known ✓ | P08588 | 7/20 | 0.87 |
| ▸ | HTR1A | P08908 | 12/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.87 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.87 |
| ▸ | LMNA | P02545 | 4/20 | 0.87 |
| ▸ | HTR2C | P28335 | 4/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.87 |
| ▸ | TSHR | P16473 | 3/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.87 |
| ▸ | DRD3 | P35462 | 3/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.87 |
| ▸ | TP53 | P04637 | 2/20 | 0.87 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.87 |
| ▸ | HTR1B | P28222 | 2/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.87 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.87 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propranolol SCHEMBL20508988 | 0.99 | HTR1A (0.85) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL29379249 | 0.93 | HTR1A (1.00) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL29908300 | 0.93 | HTR1A (1.00) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL1157882 | 0.93 | HTR1A (1.00) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL5220 | 0.93 | HTR1A (1.00) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL1157556 | 0.93 | HTR1A (1.00) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL5219 | 0.93 | HTR1A (1.00) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL2991558 | 0.92 | HTR1A (0.97) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL561162 | 0.92 | HTR1A (0.97) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL10494992 | 0.89 | HTR1A (0.91) | HTR1AADRB2ADRB1CYP1A2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4374928-A2 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | The Brigham And Women's Hospital Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-3615538-B1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-2804669-B1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE | BIOSUCCESS BIOTECH CO LTD (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230000869-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2023-01-05 | — | — | US | disclosed |
| US-20210238185-A1 | CRYSTAL FORMS OF AN ALK2 INHIBITOR | KEROS THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-11026947-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10849871-B2 | Compositions and methods of use of phorbol esters for the treatment of stroke | BIOSUCCESS BIOTECH CO., LTD. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200207697-A1 | Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke | CHANG RICHARD L (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200179389-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-11 | — | — | US | disclosed |
| US-20110039837-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100324033-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2262364-A2 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TransTech Pharma, Inc (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010114824-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TRANSTECH PHARMA INC (US) | 2010-10-07 | — | — | WO | disclosed |
| US-7790714-B2 | treating non-insulin dependent diabetes comprising administering a glucagon-like peptide receptor modulators such as (S)-2-({(S)-6-benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid | TRANSTECH PHARMA, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100197677-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7727983-B2 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | TRANSTECH PHARMA, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090306063-A1 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | TRANS TECH. PHARMA. INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009111700-A2 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-6927214-B1 | Non-peptide GLP-1 agonists | NOVO NORDISK A/S (DK) | 2005-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849871-B2 | Compositions and methods of use of phorbol esters for the treatment of stroke | PMAIP1, EBP, PLAT | ADRB2 3887/4885ADRB1 3922/4885HTR1A 4409/4885 |
| US-20200179389-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BMPR2, BMP1, BMP2K | ADRB2 3887/4885ADRB1 4353/4885HTR1A 3006/4885 |
| US-20110039837-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | ADRB2 115/4885ADRB1 56/4885HTR1A 2136/4885 |
| US-20090306063-A1 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | GLP1R, GIPR, GCGR | ADRB2 110/4885ADRB1 44/4885HTR1A 366/4885 |
| US-20100197677-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | ADRB2 115/4885ADRB1 56/4885HTR1A 2136/4885 |
| US-20230000869-A1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BMPR2, BMP1, BMP2K | ADRB2 3887/4885ADRB1 4353/4885HTR1A 3006/4885 |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | BMPR2, BMP1, BMP2K | ADRB2 3645/4885ADRB1 4225/4885HTR1A 2955/4885 |
| US-20100324033-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | ADRB2 115/4885ADRB1 56/4885HTR1A 2136/4885 |
| US-20200207697-A1 | Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke | PMAIP1, PLAT, EBP | ADRB2 3962/4885ADRB1 3990/4885HTR1A 4385/4885 |
| US-11026947-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | BMPR2, BMP1, BMP2K | ADRB2 3645/4885ADRB1 4225/4885HTR1A 2955/4885 |
| US-20210238185-A1 | CRYSTAL FORMS OF AN ALK2 INHIBITOR | ALK, ALKBH3, ACVR2A | ADRB2 1125/4885ADRB1 2253/4885HTR1A 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.